CentoICU™ – the comprehensive NGS panel
CentoICU™ is designed to diagnose genetic conditions that become present in the newborn or early childhood period. Many of these have overlapping phenotypes and diagnosis may have immediate implications for the treatment of newborns and children.
Join our next webinar on January 31, 2017; 4pm - 5pm.
What is CentoICU™?
Newborns and children under 24 months presenting with life-threatening conditions need a fast and precise diagnosis to ensure rapid and efficient further diagnostic and therapeutic initiation.
Up to one-third of all babies and children admitted to the ICU have a genetic disease. For many of them early identification can make the difference for their immediate and later health.
CentoICU™ is a comprehensive NGS panel that includes 807 genes, explicitly selected for the genetic testing of critically ill newborns and children under 24 months. It is designed to address multiple genetic conditions that may present in the newborn or first childhood period, many with overlapping phenotypes and immediate implications for treatment initiation. It allows clinicians to utilize just one single test to provide an accurate diagnosis of 807 genes and newborn-related diseases using dried blood spots.
When to recommend CentoICU™?
CentoICU™ allows clinicians to utilize one test to provide an accurate assessment for 807 newborn-related genes and associated genetic diseases using dried blood spots, and it provides fast delivery of the results in less than seven (15) days.
CentoICU™ is indicated for newborns and children under 24 months admitted to the ICU and presenting with unclear symptomatology which can be part of a genetic condition, i.e.
- Bleeding dyathesis
- Blood abnormalities (anemia)
- Bone fragility
- Failure to thrive
- Heart abnormality/arrhythmia
- Ichthyosis/epidermolysis bullosa
- Metabolic abnormalities*
- Abnormal newborn screening results**
- Respiratory failure
- Skeletal abnormalities/craniosynostosis
- Skin fragility
- Unclear seizures
*) Abnormal acylcarnitine profile, amino acidemia/urea, hyperbilirubinemia, hyper-/hypoinsulinism, persistent hypoglycemia, organic acidemia/urea
**) CentoICU™ includes genes to cover all ACMG core panel phenotypes for newborn screening except hearing loss
Why choose CENTOGENE?
Find your genetic test
What are the advantages of CentoICU™?
- Two options for delivery of results are available, with the shortest possible turnaround time:
- CentoICU™ screens 807 genes for abnormalities which allows a definite diagnosis of even very rare diseases
- Treatment and prognosis defining diagnosis for critical and rare conditions
- Co-analysis of copy number variations possible using package with CENTOGENE’s CGH array CentoArrayCyto®
Every moment counts
Earlier detection can result in less invasive and lower cost treatments for patients. It can also greatly impact the quality of a child's life.
What genes are included in CentoICU™?
CentoICU™ is designed for analysis of 807 genes and more than 100 associated conditions/phenotypes. The list of included genes was developed by our expert medical team based on several selection criteria, i.e.:
- Early onset
- Severe disease
- ICU related symptomatology
- Diseases/syndromes of differential diagnostic value
We will be happy to provide detailed information on the genes within CentoICU™ panel related to a specific set of HPO terms on request.
The following table indicates the distribution of genes depending on HPO terms in 14 categories:
|Category||Number of genes+||% of genes+|
|Newborn screening ++||25||3,1|
|Skeletal and malformation||498||61,8|
+) Due to overlapping phenotypes, particular genes are listed in more than one category.
++) Covering all core panel phenotypes as recommended by ACMG for newborn screening except hearing loss.